Condition: Advanced KRAS G12D Mutant Solid Tumors · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This is an open-label, multi-center phase I clinical study to evaluate HRS-6093 Safety, Tolerability, and Pharmacokinetics in Participants harboring KRAS G12D Mutations with advanced solid tumors. The study consists of dose escalation, dose expansion and efficacy expansion.
This description comes directly from the study's public registry record.
Rongfu Mao · +86 021-61053363 · rongfu.mao@hengrui.com
Jizhao Li · +86 021-61053363 · jizhao.li.jl565@hengrui.com
Always discuss trial participation with your own doctor first.
| Shanghai Jiao Tong University School of Medicine | Shanghai, Shanghai Municipality, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07134998